Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Namrata S. Patil, Barzin Y. Nabet, Sören Müller, et al.
Cancer Cell (2022) Vol. 40, Iss. 3, pp. 289-300.e4
Open Access | Times Cited: 273

Showing 26-50 of 273 citing articles:

Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Lenka Kašíková, Jana Raková, Michal Hensler, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 32
Tertiary lymphoid structures in anticancer immunity
Jean‐Luc Teillaud, Ana Houel, Marylou Panouillot, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 629-646
Closed Access | Times Cited: 30
An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure
Wei Liu, Wenhua You, Zhenwei Lan, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101448-101448
Open Access | Times Cited: 28
Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Katey S.S. Enfield, Emma Colliver, Claudia Lee, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 1018-1047
Open Access | Times Cited: 27
Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response
Alexander Coulton, Jun Murai, Danwen Qian, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 26
Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application
Yuyuan Zhang, Mengjun Xu, Yuqing Ren, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 25
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Miguel López de Rodas, María Villalba, Miguel F. Sanmamed, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 5
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding
Jiancheng Gao, Danling Gu, Kailin Yang, et al.
Cancer Cell (2025) Vol. 43, Iss. 1, pp. 122-143.e8
Closed Access | Times Cited: 2
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Florent Peyraud, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100546-100546
Closed Access | Times Cited: 2
Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer
Qianyu Wang, Xiaofei Shen, Ran An, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
Taiyu Shang, Tianyi Jiang, Tao Lü, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 41
Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer
Miao He, Qihua He, Xiuyu Cai, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 4, pp. e005539-e005539
Open Access | Times Cited: 40
Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non–small cell lung cancer
Brett H. Herzog, John Baer, Nicholas Borcherding, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 699
Closed Access | Times Cited: 38
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
Kezhen Li, Jing Chen, Yingjie Hu, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 76-85
Closed Access | Times Cited: 37
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Suna Zhou, Haihua Yang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 33
Single‐cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment
Guangxu Cao, Jiali Yue, Yetian Ruan, et al.
The EMBO Journal (2023) Vol. 42, Iss. 16
Open Access | Times Cited: 30
CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer
Song‐Yang Wu, Si-Wei Zhang, Ding Ma, et al.
Med (2023) Vol. 4, Iss. 6, pp. 373-393.e8
Open Access | Times Cited: 23
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Lianyu Zhao, Song Jin, Shengyao Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer
Francesca Di Modugno, Anna Di Carlo, Sheila Spada, et al.
EBioMedicine (2024) Vol. 101, pp. 105003-105003
Open Access | Times Cited: 13
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
Qianyu Wang, Wentao Zhong, Xiaofei Shen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 13
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer Research (2024) Vol. 84, Iss. 8, pp. 1199-1209
Open Access | Times Cited: 12
Immunotherapy in Sarcoma: Current Data and Promising Strategies
Georgina Wood, Christian F. Meyer, Florent Petitprez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study
Haoran Xia, Han Zhang, Zheng Ruan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer
Hao Yuan, Xingning Mao, Yunkun Yan, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Immune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma
Oscar Padilla, Hanna E. Minns, Hong-Jian Wei, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 119, Iss. 4, pp. 1248-1260
Open Access | Times Cited: 10

Scroll to top